Is it possible that GTCB is not viewed as a pure biotech but more of a drug manufacturing company using goats? GTCB just doesn't have the attention of investing community at this time because using goats to manufacture existing proteins isn't "sexy". It is my opinion that until GTCB attracts a major AMERICAN pharmaceutical company to endorse (ie partner with or hire GTCB) its novel approach to manufacturing drugs, we won't see any growth in shareholder value. I am sure GTCB's management is hard at work in trying to line up potential partners.
<<< If the chance for a similar deal would exist, the market would anticipate and we would be seeing a much higher share price. At least that would be the rationale in a normal market. In my opinion GTCB's share price performance is very abnormal >>>>
Just like the market anticipated the ALNY deal? Its very hard for the market to price in any major deal without a leak. With that said, I look forward to a day when we see GTCB up 100+% when they sign a lucrative deal.
Market Data 
Markets 
AI
